Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes - PubMed
3 days ago
- #Continuous Glucose Monitoring
- #Type 1 Diabetes
- #Tirzepatide
- Tirzepatide, a dual-incretin approved for type 2 diabetes and overweight/obesity, was studied for its effects on glucose control in overweight/obese adults with type 1 diabetes (T1D).
- The study was a single-center, retrospective, longitudinal case-control study involving 61 tirzepatide-treated and 54 matched control participants.
- Continuous glucose monitoring (CGM) data showed significant improvements in the tirzepatide group, including higher time in range (TIR) and time in tight range (TITR), and lower mean glucose and time above range (TAR).
- No increase in hypoglycemia risk was observed with tirzepatide use, and no severe hypoglycemia or diabetic ketoacidosis occurred in either group.
- A greater proportion of tirzepatide-treated participants achieved composite CGM targets (TIR ≥70% and TBR <4%) compared with controls.
- The study concludes that tirzepatide is associated with sustained improvements in CGM metrics over 12 months in overweight/obese adults with T1D, without increased hypoglycemia risk.